Status:
COMPLETED
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer. Drugs used in chemotherapy, such as ixabepilone, work in diff...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the objective response rate in patients with metastatic, recurrent, or unresectable renal cell carcinoma treated with ixabepilone. SECONDARY OBJECTIVES: I. Determin...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically or cytologically confirmed renal cell carcinoma of 1 of the following subtypes:
- Clear cell
- Papillary, type I or II
- Chromophobe
- Collecting duct
- Medullary
- Metastatic, recurrent, or unresectable disease
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- No known active brain metastases requiring steroid or anticonvulsant therapy
- Patients with definitively treated brain metastases are eligible provided they are not on steroids or anticonvulsants AND show no evidence of disease progression for ≥ 3 months after completion of definitive therapy
- Performance status - ECOG 0-2
- At least 3 months
- WBC ≥ 3,000/mm\^3
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN
- Glomerular filtration rate ≥ 50 mL/min
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No ongoing or active infection
- No HIV positivity
- No peripheral neuropathy \> grade 1
- No psychiatric illness or social situation that would preclude study compliance
- No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug
- No history of severe hypersensitivity reaction to agents containing Cremophor® EL
- No other active malignancy
- Curatively treated malignancies are allowed provided the risk of recurrent disease at the time of study enrollment is \< 20%
- No other uncontrolled illness
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No prior tubule inhibitors, including, but not limited to, any of the following:
- Vinca alkaloids (e.g., vinblastine, vincristine, or vinorelbine)
- Taxanes (e.g., docetaxel or paclitaxel)
- Epothilones
- No other concurrent chemotherapy
- See Disease Characteristics
- No concurrent hormonal therapy except steroids for adrenal failure or hypersensitivity prophylaxis or hormones for non-disease related conditions (e.g., insulin for diabetes)
- More than 4 weeks since prior radiotherapy and recovered
- No concurrent palliative radiotherapy
- No other concurrent investigational agents
- No other concurrent anticancer therapy
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00182702
Start Date
July 1 2005
Last Update
March 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States, 60637-1470